Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways.

ABSTRACT:

Background

The clinical healing environment after a posterior spinal arthrodesis surgery is one of the most clinically challenging bone-healing environments across all orthopedic interventions due to the absence of a contained space and the need to form de novo bone. Our group has previously reported that sclerostin in expressed locally at high levels throughout a developing spinal fusion. However, the role of sclerostin in controlling bone fusion remains to be established.

Methods

We computationally identified two FDA-approved drugs, as well as a single novel small-molecule drug, for their ability to disrupt the interaction between sclerostin and its receptor, LRP5/6. The drugs were tested in several in vitro biochemical assays using murine MC3T3 and MSCs, assessing their a

SUBMITTER: Sangadala S 

PROVIDER: S-EPMC10431921 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature